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Abstract
Background: COPD often coexists with chronic conditions that may influence disease prognosis. We investigated
associations between chronic (co)morbidities and exacerbations in primary care COPD patients.
Method: Retrospective cohort study based on 2012–2013 electronic health records from 179 Dutch general practices.
Comorbidities from patients with physician-diagnosed COPD were categorized according to International Classification
of Primary Care (ICPC) codes. Chi-squared tests, uni- and multivariable logistic, and Cox regression analyses were used
to study associations with exacerbations, defined as oral corticosteroid prescriptions.
Results: Fourteen thousand six hundred three patients with COPD could be studied (mean age 67 (SD 12) years, 53%
male) for two years. At baseline 12,826 (88%) suffered from ≥1 comorbidities, 3263 (22%) from ≥5. The most prevalent
comorbidities were hypertension (35%), coronary heart disease (19%), and osteoarthritis (18%). Several comorbidities
showed statistically significant associations with frequent (i.e., ≥2/year) exacerbations: heart failure (odds ratio [OR], 95%
confidence interval: 1.72; 1.38–2.14), blindness & low vision (OR 1.46; 1.21–1.75), pulmonary cancer (OR 1.85; 1.28–2.67),
depression 1.48; 1.14–1.91), prostate disorders (OR 1.50; 1.13–1.98), asthma (OR 1.36; 1.11–1.70), osteoporosis (OR 1.41;
1.11–1.80), diabetes (OR 0.80; 0.66–0.97), dyspepsia (OR 1.25; 1.03–1.50), and peripheral vascular disease (OR
1.20; 1.00–1.45). From all comorbidity categories, having another chronic respiratory disease beside COPD showed the
highest risk for developing a new exacerbation (Cox hazard ratio 1.26; 1.17–1.36).
Conclusion: Chronic comorbidities are highly prevalent in primary care COPD patients. Several chronic comorbidities
were associated with having frequent exacerbations and increased exacerbation risk.
Background
Although nowadays healthcare systems are largely
configured to manage individual diseases rather than
multimorbidity, there is an increasing awareness of the
importance of comorbidities in patients with chronic
conditions [1]. Chronic obstructive pulmonary disease
(COPD), a prevalent chronic respiratory condition, is a
major cause of morbidity and mortality worldwide [2].
In the past decade several studies have shown that
COPD often coexists with other diseases, [3, 4] and that
comorbidity is associated with poorer clinical outcomes
[4, 5]. Some of these comorbidities arise independently
of COPD, whereas others may be causally related, either
through shared risk factors (smoking, aging) or shared
pathophysiology, as a complication of COPD, or due to
medication side effects.
Several associations between COPD and particular
comorbidities have been shown. Cardiovascular disease,
metabolic syndrome, skeletal muscle dysfunction, osteo-
porosis, depression and lung cancer are all highly preva-
lent among patients with any severity of COPD, and
cross-sectional studies have shown their significant impact
on patients’ health-related quality of life [2, 6, 7]. Most of
the research on comorbidity in COPD comes from studies
in secondary care populations, thus representing patients
in the more severe part of the COPD severity spectrum
[4]. However, in most developed countries, the vast
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majority of patients with COPD are managed in primary
care. Studies performed in general practice settings report
that 21 to 74% of patients with COPD suffer from two or
more additional chronic diseases [6, 8].
As COPD is a progressive disease, factors that influ-
ence its prognosis are important to consider when man-
aging patients. Since exacerbation frequency is a known
predictor of COPD progression, [2] it is important to
know what the potential impact of comorbidities on the
risk of exacerbations is. Recently Putcha et al.reported a
model in which the number of comorbid conditions pre-
dicted dyspnea and exacerbation risk [9]. This prediction
model does, however, not take into account which
particular comorbid conditions are associated with
exacerbation risk. Other previous studies have predom-
inantly looked at mortality as the outcome of interest,
[5, 10, 11] but from a patient management perspective it
is important that physicians consider comorbidities that
influence potentially modifiable prognostic factors like
exacerbation rate in their treatment decisions. Therefore,
the aim of the current study was to explore associations
between a wide range of comorbid chronic conditions
and exacerbation risk in a real-life cohort of primary
care patients with COPD.
Methods
Design and dataset
The study used routine data from a general practice data-
base from the Department of Primary and Community
Care at the Radboud University Medical Center,
Nijmegen, the Netherlands. De-identified electronic
medical records from primary care patients diagnosed
with COPD from 179 general practices in the eastern part
of the Netherlands were available in the database.
For each registered subject, the following data were
extracted: age, sex, all diagnoses using the International
Classification of Primary Care (ICPC), extended with
Dutch ICPC sub-codes, [12] and all prescribed medication.
ICPC-2 or ICD10 coding data were recoded into ICPC-1.
Medication prescriptions (i.e., prescription start and
end dates, dosage, frequency, and duration) were ex-
tracted and categorized using the Anatomical Thera-
peutic Chemical (ATC) classification system [13]. For
the current study only the data on prescriptions for
oral corticosteroids were used.
Study population
Subjects aged ≥40 years were included in the study
population when they had physician-diagnosed COPD
(as labeled with ICPC code R95 in the electronic medical
record) before or during the study period. Asthma
(ICPC R96) in addition to the COPD code was not an
exclusion criterion. The follow-up period covered the
years 2012 and 2013. The observation period for patients
terminated either at the end of the study period (31
December 2013), or when a subject died or deregistered
from the practice.
Comorbidities
The selection of chronic comorbid diseases studied was
based on existing literature [1, 14], the authors’ clinical ex-
pertise and expert opinions (Nielen MM, Spronk I, Davids
R, Korevaar JC, Poos MJ, Hoeymans N, Opstelten W, van
der Sande MAB, Biermans MCJ, Schellevis FG, RA V: A
new method for estimating morbidity rates based on rou-
tine electronic medical records in primary care, submitted).
We considered all chronic diseases as comorbidities,
regardless whether the disease had been diagnosed before
the COPD diagnosis or thereafter. Apart from all ‘obliga-
tory’ chronic diseases we also included several recurrent dis-
eases (i.e., depression, anxiety, anemia, dyspepsia, urinary
tract infection) which could potentially influence COPD
outcomes. After reaching consensus about these recurrent
comorbidities within the research team, ICPC (sub)codes
were linked (see Appendix 1). Selection of the recurrent co-
morbidities in our population was based on the patient’s
history in terms of these particular ICPC codes. To define
whether a history of ICPC codes was relevant or irrelevant
for the aim of the study, we added specific selection criteria
based on published clinical guidelines for the respective dis-
eases (see Appendix 1).
Finally, a total of 82 chronic comorbid conditions were
selected and included in the analyses. The comorbidities
were clustered and analyzed based on their ICPC codes into
the following 14 categories: respiratory; cardiovascular;
digestive; endocrine; metabolic/nutrition; musculoskeletal;
neurologic; psychiatric; urogenital; blood (−forming or-
gans)/lymphatics; infectious; eye/ear/skin; non-pulmonary
cancer; and pulmonary cancer. Low prevalence categories
were merged (see Appendix 2). To restrict ourselves, we
focused on conditions with a high prevalence and cardio-
pulmonary comorbidities (other than COPD) with a lower
prevalence (7 conditions, see Table 2). High-prevalent
comorbidities (19 conditions), further referred to as
‘frequent comorbidities’, were defined as being present in
≥5% of the study population. This resulted in a total of 26
comorbidities remaining for further analyses.
Outcomes
The outcomes for the study were (i) prevalence of
comorbidities in the study population, (ii) annual rate of
exacerbations (dichotomized as <2 versus ≥2 exacerba-
tions/year based on the cumulated 2012/13 data), and
(iii) time (in days) until first exacerbation. An exacerba-
tion was defined as a prescription of oral corticosteroids
(i.e., prednisolone (ATC H02AB06) or prednisone (ATC
H02AB07)) with a minimum daily dose of 20 mg for a
minimum duration of 5 days and a maximum duration
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of 15 days (based on Dutch GP guidelines for treatment
of COPD exacerbations [15]). As there is no consensus
in the literature regarding a cut-off to differentiate be-
tween relapse of an earlier exacerbation and a new
exacerbation, [16] we considered a subsequent pred-
niso(lo)ne prescription after an oral corticosteroid-free
interval of ≥14 days since the end-date of the previ-
ous prescription as a new exacerbation.
Statistical analysis
Analyses were performed with SPSS statistical software
(version 22, IBM SPSS Statistics, Feltham, Middlesex,
UK) and Microsoft Excel 2007 (Microsoft Corporation,
Redmond, Washington, US). Statistically significant
results were defined as p < 0 · 05. Patients’ baseline
characteristics and comorbidity prevalence rates were
calculated. We performed Chi-square tests for catego-
rized variables and independent t-tests for continuous
variables to analyze differences between the subgroups
with <2 and ≥2 exacerbations per year.
We explored associations between comorbidities and
exacerbation risk using univariable analyses. Hazard
ratios for comorbidities were calculated using Cox
regression, in which the time variable consisted of time
to the first exacerbation. Data from patients who died or
were otherwise lost to follow up were right-censored.
Subsequently, all frequent and cardiopulmonary comor-
bidities (Table 2), age, and gender were included as
covariates in multivariate Cox regression analyses. The
model was reduced through backward exclusion to
produce a final model that consisted of only non-
collinear, independently associated, statistically signifi-
cant covariates. The same modeling approach was used
for comorbidity categories using all other categories,
with age and gender as covariates.
In addition, we performed multivariable logistic
regression analyses to calculate odds ratio’s (ORs) with
the dichotomous indicator variable for exacerbation
frequency (<2 versus ≥2 exacerbations/year) as the
dependent variable. Predictor variables in the logistic
models were: all frequent comorbidities, all cardiopul-
monary comorbidities, gender, and age. This modeling
approach was also used to analyze the 14 categories of
comorbidity.
Results
Study population
Overall, data of 16,427 subjects diagnosed with COPD
were available for analyses. Of these patients, 1824
(11 · 1%) were lost to follow-up during the 2-year
study period. Reason for loss to follow-up was known
for 800 (44 · 5%) of these patients, with death being
the predominant reason. Table 1 shows baseline char-
acteristics of the patients with complete follow-up
(i.e., the final study population, n = 14,603). Mean
(SD) age was 66 · 5 (11 · 5) years and 53% were males.
At baseline, 89 · 1% of patients suffered from ≥1
chronic comorbid conditions, while 23 · 1% had ≥5
comorbidities. Most prevalent comorbid conditions
were hypertension (35 · 2%), coronary heart disease
(19 · 2%), osteoarthritis (17 · 6%), diabetes (17 · 3%), and
peripheral vascular disease (14 · 3%). Table 2 shows the
prevalence rates of the frequent and cardiopulmonary
comorbidities. Table 3 shows the prevalence of ICPC-
categorized comorbidities.
During the 2-year study period the mean number of
exacerbations per patient was 0.72 (SD 1 · 5). 68% of
patients had no exacerbation and 5 · 7% had ≥4 exacer-
bations during the study period.
Associations between comorbidities and exacerbation
frequency
Tables 2 and 3 show the univariable associations be-
tween comorbidities and comorbidity categories and
the exacerbation frequency subgroups, respectively.
Overall, patients with one or more comorbid condi-
tions more often had ≥2 exacerbations/year compared
to patients without any comorbidity (5 · 9% vs 4 · 0%,
p = 0 · 001). Patients with any other chronic respira-
tory disease next to their COPD, (n = 2,294, 15 · 7%)
more often had ≥2 exacerbations per year compared
to patients without respiratory comorbidity (8 · 2% vs
5 · 7%, p < 0 · 001).
Univariable logistic regression analysis showed that
COPD patients with pulmonary cancer had 1.81 higher
odds for ≥2 exacerbations per year compared to patients
without pulmonary cancer (Fig. 1, p = 0.002). Patients
who, next to their COPD, also suffered from asthma,
blindness or low vision, coronary heart disease, depres-
sion, dyspepsia, heart failure, osteoporosis or osteopenia,
peripheral vascular disease, or prostate disorders, had a
higher risk of having frequent exacerbations compared
to those who did not suffer from these comorbid condi-
tions (Fig. 1).
Table 4 lists the comorbidities and comorbidity
categories significantly associated with having ≥2
exacerbation per year. In the multivariable logistic re-
gression analysis, among the statistically significant
associations, the highest ORs for having ≥2 exacerba-
tions per year were observed for pulmonary cancer
(OR 1 · 85; 95% CI 1 · 28–2 · 67), heart failure (OR 1 ·
72; 1 · 38–2 · 14), prostate disorders (OR 1 · 50; 1 · 13–
1 · 98) and blindness/low vision (OR 1 · 46; 1 · 21–1 · 75)
as comorbid conditions (Table 4). Dislipidemia was
not statistically significant, but did show a trend, with
an OR of 0 · 81 (95% CI 0 · 65–1 · 01, p = 0 · 071).
When looking at comorbidity categories, patients
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with other chronic respiratory conditions (OR 1 · 37;
1 · 15–1 · 64) and psychiatric comorbidities (OR 1 · 35;
1 · 13–1 · 60) were at highest risk for frequent
exacerbations.
Time to first exacerbation
Table 5 summarizes the results from the Cox regression
analyses. Among the statistically significant associations,
the comorbid conditions with the highest risk of devel-
oping a first exacerbation were recurrent sinusitis (Cox
hazard ratio 1 · 53; 95% CI, 1 · 05–2 · 24), bronchiectasis/
chronic bronchitis (HR = 1.50; 1.31–1.73) and heart
failure (1 · 41; 1 · 29–1 · 55). For dislipidemia a non-
statistically HR of 0 · 92 was observed (p = 0 · 067, 95%
CI 0 · 85–1 · 00).
Having another chronic respiratory disease beside
COPD was also associated with risk of developing a first
exacerbation (Cox hazard ratio 1 · 26; 1 · 17–1 · 36), see
Fig. 2.
Discussion
In this paper we explored the prevalence of comorbid
chronic conditions and associations with exacerbation
risk in a real-life cohort of primary care COPD patients.
Our findings support the notion that comorbidities are
rather rule than exception in patients with COPD [4],
with 88% having at least one other chronic disease.
Several comorbidities were associated with having fre-
quent exacerbations, with heart failure, blindness/low
vision and pulmonary cancer showing the strongest
associations in terms of statistical significance. In con-
trast, diabetes was associated with a lower risk of having
frequent exacerbations. Bronchiectasis/chronic bron-
chitis, heart failure and depression were the strongest
predictors for developing a new exacerbation.
Table 1 Baseline characteristics of the COPD study population grouped by low (<2/year) versus high (≥2/year) exacerbation rate
Patients with full follow-up (study population)a
(n = 14,603)
Subgroups of study population
Patient characteristics Patients with <2 exacerbations/year
(n = 13,709)
Patients with ≥2 exacerbations/year
(n= 894)b
Sex, male, n (%) 7,749 (53 · 1) 7,322 (53 · 4) 427 (47 · 8)‡
Age at study baseline, years;
mean (SD; range)
66 · 5 (11 · 5; 40–110)‡ 66 · 5 (11 · 6; 40–110) 67 · 4 (10 · 3; 40–93)‡
Full dataset available (censored data), n (%)
Full data available 13,709 (93 · 9) 894 (6 · 1)
Deceased N/A N/A N/A
Moved N/A N/A N/A
Nursing home N/A N/A N/A
Unknown N/A N/A N/A
Comorbidity data
Number of comorbid
diseasesc, mean (SD; range)
3 · 0 (2 · 3;0–20)‡ 3 · 0 (2 · 3;0–16) 3 · 4 (2 · 5; 0–20)‡
Number of comorbid diseases categoriesc, n (%)
0 1,777 (12 · 2) 1,700 (12 · 4) 77 (8 · 6)
1 or 2 5,305 (36 · 6) 5,021 (36 · 6) 284 (31 · 8)
3 or 4 4,258 (29 · 2) 3,977 (29 · 0) 281 (31 · 4)
5 and more 3,263 (22 · 3)‡ 3,011 (22 · 0) 252 (28 · 2)‡
Exacerbations
Number of exacerbationsd,
mean (SD; range)
0 · 75 (1 · 5;0–15)‡ 0 · 44 (0 · 8;0–2) 5 · 6 (2 · 0;3–15)‡
SD standard deviation, N/A not applicable
*p < 0.05, †p < 0.01, ‡p < 0.001
ap-values displayed are calculated for the difference between patients lost to follow-up versus patients with full follow-up. Chi-square tests for categorized variables and
independent t-tests for continuous variables. p < 0 · 05 was considered statistically significant
bp-values displayed are calculated for the difference between the subgroups <2 versus ≥2 exacerbations/year. Chi-square tests for categorized variables
and independent t-tests for continuous variables. p < 0 · 05 was considered statistically significant
cpresence of any type of comorbid disease was assessed at study baseline, i.e., 1 January 2012
dMean number of exacerbations during the study period, 1 January 2012 – 31 December 2013
Baseline characteristics of the initial population of all COPD patients (n = 16,427) and those who were lost to follow-up (n = 1,824) are reported in Appendix 3
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Comparison with existing literature
Previous research has shown that cardiovascular, psy-
chiatric, and metabolic comorbidity are highly preva-
lent in COPD patients, [8, 17] and our results
confirm these findings. In addition to the finding by
Rutten et al. [18] that unrecognized heart failure is
rather common in elderly patients with stable COPD,
our data also indicate that heart failure may increase
the risk of having frequent exacerbations. Recent clin-
ical trial data have shown correlations between several
comorbidities and mortality risk if a COPD patient is
admitted to hospital with an acute exacerbation [19, 20].
Our observations support the association between
chronic comorbidity and exacerbation risk in a pri-
mary care study population, i.e., the COPD popula-
tion without selection of any kind, which is
unprecedented and impossible to derive from clinical
trial populations [21].
We observed a trend towards statistical significance
that COPD patients with dislipidemia had less frequent
exacerbations compared to patients without dislipidemia
(HR 0.92; p = 0.067). This observation seems to be in
line with findings by Ingebrigtsen et al., who recently re-
ported that statin use for treatment of dislipidemia was
associated with reduced odds of exacerbations in indi-
viduals with COPD [22] and findings by Chan et al. that
Table 2 Prevalence of frequent and cardiopulmonary comorbidity in the study population, sorted from highest to lowest
prevalence rate
Total study populationa,
(n = 14,603)
Patients with <2 exacerbations/year,
(n = 13,709)
Patients with ≥2 exacerbations/year,
(n = 894)
p-valueb
Frequent comorbidity
Hypertension 5,116 (35 · 0) 4,805 (35 · 2) 311 (34 · 8) 0 · 873
Coronary heart disease 2,759 (18 · 9) 2,569 (18 · 7) 191 (21 · 4) 0 · 051
Osteoarthritis 2,570 (17 · 6) 2,402 (17 · 5) 168 (18 · 8) 0 · 334
Diabetes 2,464 (16 · 9) 2,330 17 · 0) 134 (15 · 0) 0 · 120
Peripheral vascular disease 2,031 (13 · 9) 1,897 (14 · 8) 150 (16 · 8) 0 · 006
Blindness & low vision 1,938 (13 · 3) 1,772 (12 · 9) 166 (18 · 6) <0 · 001
Dyspepsia, gastroesophageal reflux 1,845 (12 · 6) 1,703 (12 · 4) 142 (15 · 9) 0 · 003
Dislipidemia 1,703 (11 · 7) 1,613 (11 · 8) 90 (10 · 1) 0 · 125
Stroke & transient ischaemic attack 1,357 (9 · 3) 1,259 (9 · 2) 98 (11 · 0) 0 · 076
Chronic kidney diease 1,360 (9 · 3) 1,263 (9 · 2) 97 (10 · 9) 0 · 103
Asthma 1,305 (8 · 9) 1,202 (8 · 8) 103 (11 · 5) 0 · 005
Hearing loss 1,144 (7 · 8) 1,078 (7 · 9) 66 (7 · 4) 0 · 604
Heart failure 1,048 (7 · 2) 943 (6 · 9) 105 (11 · 7) <0 · 001
Atrial fibrillation 1,044 (7 · 1) 964 (7 · 0) 80 (8 · 9) 0 · 031
Skin cancer 913 (6 · 3) 862 (6 · 3) 51 (5 · 7) 0 · 485
Osteoporosis/osteopenia 884 (6 · 1) 801 (5 · 8) 83 (9 · 3) <0 · 001
Thyroid disorder 808 (5 · 5) 757 (5 · 5) 51 (5 · 9) 0 · 817
Depression 800 (5 · 5) 729 (5 · 3) 71 (7 · 9) 0 · 001
Prostate disorders 784 (5 · 4) 719 (5 · 2) 65 (7 · 3) 0 · 009
Cardiopulmonary comorbidity
Heart valve disease 568 (3 · 9) 528 (3 · 9) 40 (7 · 8) 0 · 035
Bronchiectasis/chronic bronchitis 414 (2 · 8) 379 (2 · 8) 35 (3 · 9) 0 · 045
Pulmonary cancer 317 (2 · 2) 284 (2 · 1) 33 (3 · 7) 0 · 001
Sleep apneu syndrome 173 (1 · 2) 161 (1 · 2) 12 (1 · 3) 0 · 653
Other chronic pulmonary disease 157 (1 · 1) 148 (1 · 1) 9 (1 · 0) 0 · 838
Recurrent sinusitis 54 (0 · 4) 49 (0 · 4) 55 (6 · 2) 0 · 335
Congenital cardiovascular anomaly 32 (0 · 2) 28 (0 · 2) 4 (0 · 4) 0 · 132
aCOPD population with complete data available, patients lost to follow-up (n = 1,824) excluded
bp-values displayed are calculated for the difference between the subgroup <2 versus ≥2 exacerbations/year Chi-square tests for categorized variables. p < 0 · 05
was considered statistically significant
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hyperlipidemia in COPD was associated with decreased
incidence of pneumonia and mortality in retrospective
analyses of health insurance data [23]. Intuitively, the
observed lower risk of frequent exacerbations in COPD
patients with comorbid diabetes might be sought in GPs’
reluctance to prescribe oral corticosteroids in these
patients because the impact this may have on glucose
levels, but a survey among Dutch GPs showed that
most of them do not adjust treatment of exacerba-
tions to the presence of diabetic comorbidity [24].
Gastroesophageal reflux disease (OR = 1.25 (95% CI
1.03–1.50) in our analyses) was recognized as a
significant predictor of acute exacerbations of COPD
in a recent review by Lee et al [25]. A relationship
between prostate disorders and exacerbations has not
been described in the literature, but might be related
to use of inhaled anticholinergics.
Strengths and limitations
A strength of this study is the inclusion of >14 thousand
COPD patients from a real-life, unbiased primary care
setting. However, the main strength is not so much the
uniqueness or even the size of our dataset. Other exist-
ing general practice databases essentially contain the
same, or even more detailed data regarding diagnoses
and medication prescriptions, [26–29] but the meticu-
lousness with which we have looked at ALL chronic
comorbidity, including recurrent episodes of conditions
that are not necessarily chronic in all patients, seems un-
precedented. Moreover, other existing databases with
real-life general practice COPD data mainly stem from
the UK and Denmark, and now there is also one avail-
able from the Netherlands. We intentionally applied
minimal exclusion criteria in order to maximize
generalizability of the results. Another strength is the
wide range of chronic comorbidities investigated,
summing up to a total of 82 conditions. Apart from all
commonly known chronic comorbid diseases, we also
included several recurrent diseases (i.e., depression,
anxiety, anemia, dyspepsia, urinary tract infection) and
applied criteria to define their chronicity based on
disease specific guidelines (see Appendix 1). Inclusion of
patients with recurrent diseases seems relevant when
studying risk factors for COPD exacerbations, but has
not been done in previous studies.
Our study was based on patients’ medical records in
general practice. Limited agreement between medical
record-based and objectively identified comorbidities of
COPD [30] and undiagnosed comorbidity in COPD
patients is common [18, 31]. This may have resulted in
underestimation of the presence of comorbidity in our
Table 3 Prevalence of ICPC-categorized comorbidity in the COPD study population, sorted from highest to lowest prevalence rate
of frequent exacerbations
Study populationa,
(n = 14,603)
Patients with <2 exacerbations/year,
(n = 13,709)
Patients with ≥2 exacerbations/year
(n = 894)
p-valueb
Comorbidity category
Cardiovascular 8,516 (58 · 3) 7,955 (58 · 0) 561 (62 · 8) 0 · 006
Endocrine, metabolic and nutrition 4,856 (33 · 3) 4,568 (33 · 3) 288 (25 · 5) 0 · 496
Musculoskeletal 3,588 (24 · 6) 3,337 (24 · 3) 251 (28 · 1) 0 · 012
Eye and ear 2,984 (20 · 4) 2,762 (20 · 1) 222 (24 · 8) 0 · 001
Digestive 2,801 (19 · 2) 2,597 (18 · 9) 204 (22 · 8) 0 · 004
Urogenital (male and female) 2,330 (16 · 0) 2,146 (15 · 7) 184 (20 · 6) <0 · 001
Psychiatric 2,271 (15 · 6) 2,092 (15 · 3) 179 (20 · 0) <0 · 001
Non-pulmonary cancer 2,203 (15 · 1) 2,071 (15 · 1) 132 (14 · 8) 0 · 782
Respiratory (excl · pulmonary cancer) 1,998 (13 · 7) 1,839 (13 · 4) 159 (17 · 8) <0 · 001
Skin 1,395 (9 · 6) 1,314 (9 · 6) 81 (9 · 1) 0 · 605
Neurological 413 (2 · 8) 389 (2 · 8) 24 (2 · 7) 0 · 789
Pulmonary cancer 317 (2 · 2) 284 (2 · 1) 33 (3 · 7) 0 · 001
Blood (forming organs) and lymphatics 106 (0 · 7) 97 (0 · 7) 9 (1 · 0) 0 · 307
Infectious 87 (0 · 6) 80 (0 · 6) 7 (0 · 8) 0 · 453
ICPC International Classification of Primary Care
aTotal COPD population, with patients who were lost to follow-up (n = 1,824) excluded
bp-values displayed are calculated for the difference between the group <2 versus ≥2 exacerbations/year. We performed Chi-square tests for categorized variables.
p-value <0 · 05 was considered statistically significant
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Fig. 1 Comorbidome of comorbidities in the COPD study population (n = 14,603). Results are from univariable (upper panel) and multivariable
(lower panel, corrected for age, gender and the other comorbidities) logistic regression analysis. (Diameter of the coloured circles represents the
prevalence of each comorbidity. Proximity to the black centre of the circle represents stronger positive association (OR) with ≥2 exacerbation per
year. The dashed circle represents an OR of 1. Comorbidities marked bold were statistically significantly (i.e., p < 0.05) associated with increased or
decreased risk. In the multivariable model covariates were sequentially dropped until only statistically significant covariates remained.
Comorbidities outside the dashed circle were negatively associated (i.e., ‘protective’) with ≥2 exacerbation/year. Comorbidities with prevalence
<5% were not analysed). CKD: chronic kidney disease. COPD: chronic obstructive pulmonary disease. GERD: gastroesophageal reflux disease. TIA:
transient ischemic attack
Westerik et al. Respiratory Research  (2017) 18:31 Page 7 of 17
study population. The use of real-life data presents limi-
tations, for instance the fact that patients’ smoking
history and lung function could not be included because
this information is not consistently and uniformly
documented in general practice medical records. We
chose to limit the analyses to comorbidities with a rela-
tively high (i.e., ≥5%) prevalence. This may mean that
comorbidities that are related to increased exacerbation
risk but have a low prevalence rate in the COPD patient
population were missed.
We defined an exacerbation as an oral corticosteroid
prescription, which is the recommended treatment for
acute exacerbations in Dutch COPD guidelines [15].
Consequently, mild exacerbations treated with broncho-
dilators only are not included in our analyses. Oral ster-
oid prescriptions during GP out-of-office hours,
emergency department visits and hospitalizations, and
prescriptions by pulmonary specialists may not always
have been included for all patients, as these are not
automatically added to patients’ medical records in all
electronic patient record systems. Because there is no
international consensus about a definition that discrimi-
nates relapse of an earlier exacerbation from a new one,
our (arbitrary) choice to use an interval of ≥14 days
since the end date of the previous oral steroid prescrip-
tion may have led to under- or overestimation of the
number of exacerbations. Unfortunately, the rather
crude prescription information did not allow us to look
at the impact of comorbidities on the duration or pro-
gression of exacerbations. Although observational
studies such as ours lack the rigorous internal validity
that is typical for randomized controlled trials, they pro-
vide valuable insight into comorbidity prevalence in
COPD and its relation with an important outcome, i.e.,
exacerbations. As such, our findings should be consid-
ered in conjunction with those arising from other study
designs, including randomized trials.
Table 5 Comorbidities associated with development of a first
exacerbation in the study population, corrected for age and sex
(results from multivariable Cox regression analysis), sorted by p-value
Cox hazard ratio (95% CI) p-value
Comorbiditya,b
Bronchiectasis/chronic bronchitis 1 · 50 (1 · 31–1 · 73) <0 · 001
Heart failure 1 · 41 (1 · 29–1 · 55) <0 · 001
Depression 1 · 34 (1 · 20–1 · 50) <0 · 001
Atrial fibrillation 1 · 27 (1 · 16–1 · 40) <0 · 001
Asthma 1 · 24 (1 · 14–1 · 36) <0 · 001
Peripheral vascular disease 1 · 15 (1 · 07–1 · 24) <0 · 001
Prostate disorders 1 · 20 (1 · 04–1 · 45) 0 · 002
Blindness & low vision 1 · 11 (1 · 03–1 · 20) 0 · 009
Coronary heart disease 1 · 10 (1 · 02–1 · 17) 0 · 011
Dyspepsia, gastroesophageal
reflux
1 · 10 (1 · 02–1 · 20) 0 · 013
Pulmonary cancer 1 · 23 (1 · 04–1 · 45) 0 · 016
Recurrent sinusitis 1 · 53 (1 · 05–2 · 24) 0 · 028
Osteoporosis/osteopenia 1 · 12 (1 · 01–1 · 25) 0 · 037
Comorbidity categoryb, c
Respiratory (excl. pulmonary
cancer)
1 · 26 (1 · 17–1 · 36) <0 · 001
Urogenital (male and female) 1 · 18 (1 · 10–1 · 27) <0 · 001
Cardiovascular 1 · 16 (1 · 08–1 · 24) <0 · 001
Mental health 1 · 16 (1 · 08–1 · 24) <0 · 001
Eye and ear 1 · 09 (1 · 02–1 · 16) 0 · 013
Digestive 1 · 07 (1 · 00–1 · 15) 0 · 042
aAll chronic comorbidities with prevalence ≥5% and cardiopulmonary
comorbidities were included in the multivariate Cox regression model
bReference category was ‘comorbidity not diagnosed before study period’ (i.e.,
1 January, 2012)
cAll ICPC comorbidity categories were included in the multivariate Cox
regression model
Table 4 Comorbidities associated with ≥2 exacerbations/year
versus <2 exacerbations/year in COPD patients, corrected for
age and sex (multivariable results), sorted by p-value
Odds ratio (95%CI) p-value
Comorbid conditionsa, b
Heart failure 1 · 72 (1 · 38–2 · 14) <0 · 001
Blindness & low vision 1 · 46 (1 · 21–1 · 75) <0 · 001
Pulmonary cancer 1 · 85 (1 · 28–2 · 67) 0 · 002
Depression 1 · 48 (1 · 14–1 · 91) 0 · 003
Prostate disorders 1 · 50 (1 · 13–1 · 98) 0 · 004
Asthma 1 · 36 (1 · 11–1 · 70) 0 · 004
Osteoporosis/osteopenia 1 · 41 (1 · 11–1 · 80) 0 · 006
Diabetes 0 · 80 (0 · 66–0 · 97) 0 · 020
Dyspepsia, gastroesophageal reflux 1 · 25 (1 · 03–1 · 50) 0 · 023
Peripheral vascular disease 1 · 20 (1 · 00–1 · 45) 0 · 049
Comorbidity categoriesb,c
Respiratory (excl. pulmonary cancer) 1 · 37 (1 · 15–1 · 64) <0 · 001
Psychiatric 1 · 35 (1 · 13–1 · 60) <0 · 001
Urogenital (male and female) 1 · 34 (1 · 12–1 · 60) <0 · 001
Eye and ear 1 · 25 (1 · 06–1 · 47) 0 · 007
Endocrine, metabolic and feeding 0 · 85 (0 · 73–0 · 99) 0 · 032
Cardiovascular 1 · 17 (1 · 01–1 · 36) 0 · 037
OR odds ratio
aAll chronic comorbidities with prevalence ≥5% and cardiopulmonary
comorbidities were included in the multivariable logistic regression model
bReference category was ‘comorbidity not diagnosed before study period’
(i.e., 1 January 2012)
cAll ICPC comorbidity categories were included in the multivariate logistic
regression mode
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Clinical implications
Better knowledge about the role that comorbidity plays
in COPD exacerbation risk may contribute to lower
exacerbation rates in COPD patients through patient-
tailored and systems medicine approaches. In turn,
reduction of exacerbations may improve patients’ quality
of life and prevent disability, hospitalizations, and mor-
tality. A challenge for researchers is to find ways to
enable physicians to take comorbidity into account when
assessing COPD patients’ exacerbation risk. Putcha et al.
developed a simple score that includes 14 comorbidities,
where one point increase in comorbidity count was asso-
ciated with 21% higher exacerbation risk [9]. However,
their comorbidity score does not include comorbidities
such as asthma, lung cancer and depression, while our
results indicate that these comorbidities are also related
to exacerbation risk. Neither does Putcha’s score take
differences in exacerbation risk for different comorbidi-
ties into account. This highlights the importance of in-
cluding a wide range of comorbid chronic conditions
like we did in our study.
Beside Putcha’s comorbidity score, several prognostic
indices to support COPD patient care have been devel-
oped, [32] most of them predicting prognosis in terms of
mortality or hospitalization. Only few indices predict ex-
acerbation risk and only one (the DOSE index [33]) has
been developed and validated in primary care [34].
Comorbidity is not included in the existing prognostic
indices, with the exception of the COTE index, which
assesses mortality and not exacerbation risk [10, 11].
Our results may contribute to the development of a
prognostic index that connects comorbidities with ex-
acerbation risk to identify patients at highest risk,
thereby potentially reducing disease progression.
Conclusion
We have confirmed that many patients with COPD are
affected by chronic comorbidities. Several highly preva-
lent as well as cardiopulmonary comorbidities appear to
be independently associated with the risk of suffering
from frequent exacerbations in our unbiased primary
care patient population. Apart from clinical COPD
guidelines advising that comorbidities should be diag-
nosed and treated appropriately, insight in patients’ co-
morbidity patterns could also be used to identify those
that are more likely to suffer from frequent exacerba-
tions. Further research is needed to assess opportunities
of implementation of this knowledge in routine care, so
that patient-centered COPD care that also takes comor-
bidity into account can become the standard. Ultimately
this may contribute to reducing disease progression and
reduce the significant burden that COPD and its exacer-
bations puts on patients and healthcare systems.
Fig. 2 Hazard for exacerbation split by COPD patients with versus without one or more diagnoses of other chronic respiratory diseases at
baseline. (Patients with another chronic respiratory disease next to their COPD showed a higher hazard rate for the development of a first
exacerbation (Cox hazard ratio 1.26; 1.17–1.36) compared to patients without another chronic respiratory disease). COPD: chronic obstructive
pulmonary disease
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Appendix 1
Table 6 List of 82 comorbidities included in comorbidity selection, sorted by prevalence (%) in the study population
Comorbiditiy Prevalence (%) Diagnosis ICPC code Inclusion criteria
Hypertension 35.2 Hypertension K86, K87 ICPC code before 1-1-12
Coronary heart disease 19.2 Myocardial infarction/other
ischemic heart disease
K75, K76, K76.02,
K76.01
ICPC code before 1-1-12
Angina Pectoris K74, K74.01, K74.02 ICPC code before 1-1-12
Osteoarthritis 17.6 Artrose/spondylose
wervelkolom
L84, L84.01, L84.02 ICPC code before 1-1-12
Gonartrose L90 ICPC code before 1-1-12
Coxartrose L89 ICPC code before 1-1-12
Osteoarhritis, other L91 ICPC code before 1-1-12
Diabetes 17.3 DM1, DM2 T90, T90.01, T90.02 ICPC code before 1-1-12
Peripheral vascular disease 14.3 Atherosclerose K91 ICPC code before 1-1-12
Intermittent claudication/
Raynaud/Buerger
K92, K92.01, K92.02,
K92.03
ICPC code before 1-1-12
Other disease cardiovascular
system
K99, K99.01, K99.02, K
99.03, K99.04, K99.05,
K99.06
ICPC code before 1-1-12
Blindness & low vision 13.8 (Diabetic/hypertensive)
retinopathy
F83, F83.01, F83.02 ICPC code before 1-1-12
Maculadegeneratie F84 ICPC code before 1-1-12
Blindness/amblyopia F94 ICPC code before 1-1-12
Cataract F92, F92.01 ICPC code before 1-1-12
Dyspepsia, Gastroesophageal
reflux (GERD)
12.6 Stomach ulcer D86.01 ICPC code before 1-1-12 AND (recode
OR connection to episode) 12 months
after first ICPC [35]
Duodenal ulcer D85 ICPC code before 1-1-12 AND (recode
OR connection to episode) 12 months
after first ICPC [35]
Peptic ulcer, other D86 ICPC code before 1-1-12 AND (recode
OR connection to episode) 12 months
after first ICPC [35]
Oesophagus reflux with
and without oesophagitis
D87, D87.01, D87.02,
D84, D84.02, D84.03
ICPC code before 1-1-12 AND (recode
OR connection to episode) 12 months
after first ICPC [35]
Dislipidemia 11.5 Hypercholesterolemia/
hypertriglyceridemia
T93, T93.01, T93.02,
T93.03, T93.04
ICPC code before 1-1-12
Stroke & transient ischaemic
attack
9.7 TIA (transient ischemic
accident)
K89 ICPC code before 1-1-12
CVA (cerebrovascular accident) K90, K90.01, K90.02,
K90.03
ICPC code before 1-1-12
Chronic kidney diease 9.5 Renal dysfunction U99, U99.01 ICPC code before 1-1-12
Asthma 8.5 Asthma R96, R96.01, R96.02 ICPC code before 1-1-2012 AND (recode
OR connection to episode) 24 months
after first ICPC code [36]
Hearing loss 8.1 Deafness H84, H86, H85 ICPC code before 1-1-12
Otosclerosis H83 ICPC code before 1-1-12
Heart failure 7.9 (congestive) heart failure K77, K77.01, K77.02 ICPC code before 1-1-12
Pulmonary heart disease K82 ICPC code before 1-1-12
Atrial fibrillation 7.5 Atrial fibrillation/flutter K78 ICPC code before 1-1-12
Skin cancer 6.3 Skin cancer ICPC code before 1-1-12
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Table 6 List of 82 comorbidities included in comorbidity selection, sorted by prevalence (%) in the study population (Continued)
S77.01, S77.02,
S77.03, S77.04, S77
Osteoporosis/osteopenia 6.3 Osteoporosis/osteopenie L95, L95.01, L95.02 ICPC code before 1-1-12
Depression 5.6 Depressive disorder P76, P76.01 ICPC code before 1-1-2012 AND (recode
OR connection to episode) 24 months
after first ICPC code [37, 38]
Thyroid disorder 5.6 Hypothyroidism T86 ICPC code before 1-1-12
Hyperthyroidism T85 ICPC code before 1-1-12
Psoariasis 4.6 Psoriasis S91 ICPC code before 1-1-12
Obesity 4.4 Adipositas T82 ICPC code before 1-1-12
Anxiety 4.3 Somatoform disorder P75 ICPC code before 1-1-2012 AND (recode
OR connection to episode) 24 months
after first ICPC code [39]
Phobia P79.01 ICPC code before 1-1-2012 AND (recode
OR connection to episode) 24 months
after first ICPC code [39]
Anxiety disorder P74, P 74.01, P74.02 ICPC code before 1-1-2012 AND (recode
OR connection to episode) 24 months
after first ICPC code [39]
Obsessive - compulsive
disorder
P79.02 ICPC code before 1-1-2012 AND (recode
OR connection to episode) 24 months
after first ICPC code [39]
(chronic) functional somatic
symtoms
P01, P78 ICPC code before 1-1-2012 AND (recode
OR connection to episode) 24 months
after first ICPC code [39]
Post traumatic stress disorder P02.01 ICPC code before 1-1-2012 AND (recode
OR connection to episode) 24 months
after first ICPC code [39]
Eczema 4.1 Atopic dermatitis S87 ICPC code before 1-1-12
Heart valve disease 3.9 Heart valve disease K83, K83.01, K83.02 ICPC code before 1-1-12
Heart valve disease (rheumatic) K71.02 ICPC code before 1-1-12
Diverticular disease of
intestine
3.9 Colonic diverticula, diverticulitis D92 ICPC code before 1-1-12
Alcohol problems 3.9 Chronic alcohol abuse P15, P15.01, P15.02,
P15.03, P15.04,
P15.05, P15.06
ICPC code before 1-1-12
Rheumatoid arthritis, other
inflammatory polyarthropathies
& systemic connective tissue
disorders
3.7 Rheumatoid arthritis/
ankylosing spondylarthritis
L88.01, L88.02, L88 ICPC code before 1-1-12
Bronchiectasis/chronic bronchitis 2.8 Bronchiectasis/Chronic
bronchitis
R91.02, R91, R91.01 ICPC code before 1-1-12
Irritable bowel syndrome 2.8 Irritable bowel syndrom D93 ICPC code before 1-1-12
Venous insufficiency 2.4 Venous insufficiency K99.04 ICPC code before 1-1-12
Varicose ulcer S97, S97.01 ICPC code AND (recode OR connection
to episode) 3 months after first
ICPC code [40]
Pulmonary cancer 2.4 lung/bronchial cancer R84 ICPC code before 1-1-12
Recurrent urinary tract infection 2.3 Urinary tract infection,
chronic/recurrent
U71, U71.01, U71.02 ICPC code AND (recode OR connection
to episode) ≥3 times/year in 2011, 2012,
2013. Years start with 1e ICPC code.
Minimal 8 weeks between each
episode [41]
Breast cancer 2.3 Breat cancer X76, X76.01 ICPC code before 1-1-12
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Table 6 List of 82 comorbidities included in comorbidity selection, sorted by prevalence (%) in the study population (Continued)
Glaucoma 2.2 Glaucoma/verhoogde
oogboldruk
F93, F93.01, F93.02,
F93.03, F93.04
ICPC code before 1-1-12
Gout 2.0 Gout T92 ICPC code AND (recode OR connection
to episode) ≥3 times/year in 2011, 2012,
2013. Years start with 1e ICPC code.
Minimal 22 days between each
episode [42]
Prostate cancer 1.9 Prostate cancer Y77 ICPC code before 1-1-12
Dementia 1.7 Alzheimer's disease/Senil
dementia/Alzheimer/Multi-
infarct dementia
P70.01, P70, P70.02 ICPC code before 1-1-12
Colorectal cancer 1.7 Colon cancer D75 ICPC code before 1-1-12
Rectal cancer D75 ICPC code before 1-1-12
Epilepsy 1.4 Epilepsy N88 ICPC code before 1-1-12
Bladder cancer 1.3 Bladder cancer U76 ICPC code before 1-1-12
Sleep apnea syndrome 1.2 Sleep apnea syndrome P0601 ICPC code before 1-1-12
Underfeeding/vitamine
deficiency
1.2 Underfeeding/vitamine
deficiency
T91, T05 ICPC code before 1-1-12 AND (recode
OR connection to episode) 12 months
after first ICPC
Inflammatory bowel disease 1.2 Crohn's disease/Ulcerative
colitis
D94, D94.01, D94.02 ICPC code before 1-1-12
Personality disorder 1.2 Personality disorder P80, P80.01, P80.02 ICPC code before 1-1-12
Prostate disorders 1.2 Prostatic hyperplasia/
hypertrophy
Y85 ICPC code before 1-1-12
Other chronic pulmonary disease 1.1 Pulmonary tuberculosis R70 ICPC code before 1-1-12
Pneumoconiosis R99.06 ICPC code before 1-1-12
Sarcoidosis R83.02 ICPC code before 1-1-12
Chronic liver disease 1 Cirrose/steatose D97, D97.04, D97.05 ICPC code before 1-1-12
Genitourinary cancer, other 0.9 Genitourinary cancer, other U75, U77, X77, Y78,
Y78.01, Y78.03
ICPC code before 1-1-12
Blood(forming organs) and
lymphatics disorder
0.8 Benign non specified neoplasm
blood/lymphatic disorder
B75 ICPC code before 1-1-12 AND (recode
OR connection to episode) 12 months
after first ICPC [43]
Haemophilia B83.01 ICPC code before 1-1-12
Congenital blood/lymphatic
disorder
B79 ICPC code before 1-1-12
Purpura/coagulation disorders/
abnormal trombocytes
B83, B83.02, B83.06 ICPC code before 1-1-12
Schrizophrenia/non-organic
psychosis/bipolar disorder
0.8 Schizophrenia P72 ICPC code before 1-1-12
Psychosis non specified P98 ICPC code before 1-1-12
Bipolar P73.02 ICPC code before 1-1-12
Migraine 0.8 Migraine N89 ICPC code before 1-1-12 AND (recode
OR connection to episode) 12 months
after first ICPC [44]
Cancer oropharynx, oesophageal,
stomach
0.8 Cancer of the mouth/pharynx D77.02, D77.03 ICPC code before 1-1-12
Oesophageal cancer D77.01, D77 ICPC code before 1-1-12
Cancer of stomach D74 ICPC code before 1-1-12
Other psychoactive substance
misuse
0.7 Substance abuse P19, P19.01, P19.02 ICPC code before 1-1-12
Parkinson's disease 0.6 Parkinson's disease N87.01, N87 ICPC code before 1-1-12
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Table 6 List of 82 comorbidities included in comorbidity selection, sorted by prevalence (%) in the study population (Continued)
Other chronic skin disease/
neoplasm (sub)cutis
0.6 Neoplasm cutis, subcutis
non specified
S80, S80.01, S81, S83,
S83.01, S83.02
ICPC code before 1-1-12
Vitiligo/lichen planus S99.04, S99.06 ICPC code before 1-1-12
Viral hepatitis 0.6 Hepatitis B D72.02, D72.04 ICPC code before 1-1-12
Hepatitis C D72.03, D72.05 ICPC code before 1-1-12
Hepatitis D72 ICPC code before 1-1-12
Uterine cervical cancer 0.5 Uterine cervical cancer X75 ICPC code before 1-1-12
Learning disability’/Mental
retardation
0.4 Mental retardation P85 ICPC code before 1-1-12
Specified learning problems P24. P24.01, P24.02,
P24.03
ICPC code before 1-1-12
Laryngeal/throat cancer 0.4 Laryngeal/troat cancer R85 ICPC code before 1-1-12
Hodgkin disease 0.4 Hodgkin disease B72, B72.01, B72.02 ICPC code before 1-1-12
Carcinoma, other 0.4 Carcinoma, other D77.04, T71, W72,
L71, L71.01
ICPC code before 1-1-12
Chronic sinusitis 0.3 Chronic sinusitis R75.02 ICPC code before 1-1-12
Acute Sinusitis R75.01 en R75 ICPC code AND (recode OR connection
to episode) ≥3×/year in 2011, 2012, 2013.
Years start with 1e ICPC code. Minimal
29 days between each episode. [45]
Glomerulonephritis/nephrosis 0.3 Glomerulonephritis U88 ICPC code before 1-1-12
Congenital cardiovascular
anomaly
0.2 Congenital cardiovascular
anomaly
K73, K73.01, K73.02 ICPC code before 1-1-12
Leukaemia 0.2 Leukaemia B73 ICPC code before 1-1-12
Lymphoma/multiple myeloma/
other blood cancer
0.2 Lymphoma/multiple myeloma/
other blood cancer
B74.01, B74 ICPC code before 1-1-12
Anaemia 0.1 Pernicous/folic acid anaemia B81, B81.01, B81.02 ICPC code before 1-1-12 AND (recode
OR connection to episode) 12 months
after first ICPC [43]
Haemolytic anaemia B78, B78.01, B78.02,
B78.03
ICPC code before 1-1-12
Anorextia or bulimia 0.1 Anorexia nervosa T06, T06.01, T06.02 ICPC code before 1-1-12
Coeliakie 0.1 Coeliakie D99.06 ICPC code before 1-1-12
Endometrial cancer 0.1 Endometrial cancer X77.01 ICPC code before 1-1-12
Metastases; unknown origin 0.1 Metastases; unknown origin A79 ICPC code before 1-1-12
Multiple sclerosis 0.1 MS (multiple sclerosis) N86 ICPC code before 1-1-12
Ovarian cancer 0.1 Ovarian cancer X77.02 ICPC code before 1-1-12
Pancreatic cancer 0.1 Pancreatic cancer D76 ICPC code before 1-1-12
Testis cancer 0.1 Testis cancer Y78.02 ICPC code before 1-1-12
Brain cancer (recall: Nervous
system cancer)
0 Brain cancer (recall: Nervous
system cancer)
N74 ICPC code before 1-1-12
HIV/AIDS 0 HIV; AIDS B90, B90.01, B90.02 ICPC code before 1-1-12
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Appendix 2
Table 7 List of comorbidity categories
Categories of chronic disease Disease
Cardiovascular Hypertension
Coronary heart disease
Congenital cardiovascular anomaly
Heart failure
Stroke & transient ischaemic attack
Atrial fibrillation
Heart valve disease
Venous insufficiency
Peripheral vascular disease
Respiratory COPD
Asthma
Sleep apnea syndrome
Chronic sinusitis
Other chronic pulmonary disease
Bronchiectasis/chronic bronchitis
Mental Health Depression
Anxiety disorder
Alcohol problems
Other psychoactive substance misuse
Schrizophrenia/non-organic psychosis/
bipolar disorder
Anorextia or bulimia
Personality disorder
Learning disability’/Mental retardation
Musculoskeletal Rheumatoid arthritis, other inflammatory
polyarthropathies & systemic connective
tissue disorders
Gout
Osteoporosis/osteopenie
Osteoarthritis
Eye and Ear Hearing loss
Glaucoma
Blindness & low vision
Urogenital (Male and female) Chronic kidney diease
Glomerulonephritis/nephrosis
Recurrent urinary tract infection
Prostate disorders
Skin Eczema
Psoriasis
Other chronic skin disease/neoplasm
(sub)cutis
Table 7 List of comorbidity categories (Continued)
Digestive Diverticular disease of intestine
Dyspepsia, Gastroesophageal reflux
Irritable bowel syndrom
Inflammatory bowel disease
Coeliakie
Chronic liver disease
Endocrine, metabolic
and nutrition
Underfeeding/vitamine deficiency
Diabetes
Dislipidemia
Obesity
Thyroid disorder
Neurological Dementia
Epilepsy
Migraine
Parkinson's disease
Multiple sclerosis
Blood(forming organs) and
Lymphatics
Anaemia
Blood (forming organs) and lymphatics
disorder
Infectious Viral hepatitis
HIV/AIDS
Non-pulmonary cancer Testis Cancer
Cancer oropharynx, oesophageal,
stomach
Cancer Colorectal
Pancreatic cancer
Laryngeal/troat cancer
Breast cancer
Ovarian cancer
Endometrial cancer
Uterine cervical cancer
Prostate cancer
Bladder cancer
Genitourinary cancer, other
Brain cancer (recall: Nervous system
cancer)
Hodgkin disease
Leukaemia
Lymphoma/multiple myeloma/other
blood cancer
Metastases; unknown origin
Carcinoma, other
Skin cancer
Pulmonary cancer Pulmonary cancer
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Table 8 Baseline characteristics of the initial population of all COPD patients, the patients who were lost to follow-up, and the patients
with full follow-up
All COPD patients
(n=16,427)
Patients lost to follow-up
(n= 1,824)
Patients with full follow-up (study population)a
(n=14,603)
Patient characteristics
Sex, male, n (%) 8,682 (52·9) 933 (51·2) 7,749 (53·1)
Age at study baseline, years; mean (SD; range) 66·9 (11·6; 40–111) 70·1 (12·0; 40–111) 66·5 (11·5; 40–110)‡
Full dataset available (censored data), n (%)
Full data available 14,603 (88·7)
Deceased 541 (3·0) 541 (29·7) N/A
Moved 223 (1·3) 223 (12·2) N/A
Nursing home 36 (0·2) 36 (2·0) N/A
Unknown 1024 (6·2) 1024 (56·1) N/A
Comorbidity data
Number of comorbid diseasesb, mean (SD; range) 3·0 (2·3;0–20) 3·4 (2·5; 0–16) 3·0 (2·3;0–20)‡
Number of comorbid diseases categoriesb, n (%)
0 1,951 (11·9) 174 (9·5) 1,777 (12·2)
1 or 2 5,891 (35·9) 586 (32·1) 5,305 (36·6)
3 or 4 4,797 (29·2) 539 (29·6) 4,258 (29·2)
5 and more 3,788 (23·1) 525 (28·8) 3,263 (22·3)‡
Exacerbations data
Number of exacerbations, mean (SD; range) 0·72 (1·5;0–15)c 0·46 (1·0;0–11)c 0·75 (1·5;0–15)
SD standard deviation, N/A not applicable
*p<0.05, †p<0.01, ‡p<0.001
ap-values displayed are calculated for the difference between patients lost to follow-up versus patients with full follow-up. Chi-square tests for categorized variables and
independent t-tests for continuous variables. p<0·05 was considered statistically significant
bPresence of any type of comorbid disease was assessed at study baseline, i.e. 1 January 2012
cMean number of exacerbations during the study period, 1 January 2012 – 31 December 2013. For the columns ‘all COPD patients’ and ‘Patients lost to follow-up’
these rates cannot be converted into annual rates because of incomplete observation time in the patients who were lost to follow-up
Baseline characteristics of the study population grouped by low (<2/year) versus high (≥2/year) exacerbation rate are reported in Table 1
Westerik et al. Respiratory Research  (2017) 18:31 Page 15 of 17
References
1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology
of multimorbidity and implications for health care, research, and medical
education: a cross-sectional study. Lancet (London, England). 2012;
380(9836):37–43.
2. From the Global Strategy for the Diagnosis, Management and Prevention of
COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016.
Available from: http://www.goldcopd.org/. Accessed 16 Jan 2017.
3. van Manen JG, IJzermans CJ, Bindels PJ, van der Zee JS, Bottema BJ, Schade
E. Prevalence of comorbidity in patients with a chronic airway obstruction
and controls over the age of 40. J Clin Epidemiol. 2001;54(3):287–93.
4. Negewo NA, McDonald VM, Gibson PG. Comorbidity in chronic obstructive
pulmonary disease. Respir Invest. 2015;53(6):249–58.
5. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic
obstructive pulmonary disease: prevalence, influence on outcomes, and
management. Semin Respir Crit Care Med. 2015;36(4):575–91.
6. Wijnhoven HA, Kriegsman DM, Hesselink AE, de Haan M, Schellevis FG. The
influence of co-morbidity on health-related quality of life in asthma and
COPD patients. Respir Med. 2003;97(5):468–75.
7. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular
comorbidity in patients with chronic obstructive pulmonary disease: a
systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.
8. Garcia-Olmos L, Alberquilla A, Ayala V, Garcia-Sagredo P, Morales L,
Carmona M, et al. Comorbidity in patients with chronic obstructive
pulmonary disease in family practice: a cross sectional study. BMC Fam
Pract. 2013;14:11.
9. Putcha N, Puhan MA, Drummond MB, Han MK, Regan EA, Hanania NA, et al. A
simplified score to quantify comorbidity in COPD. PLoS One. 2014;9(12):e114438.
10. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al.
Comorbidities and risk of mortality in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61.
11. de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Divo M, Zulueta JJ, et al.
Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the
COPD comorbidity index COTE. Thorax. 2014;69(9):799–804.
12. Okkes IM, Becker HW, Bernstein RM, Lamberts H. The March 2002 update of
the electronic version of ICPC-2. A step forward to the use of ICD-10 as a
nomenclature and a terminology for ICPC-2. Fam Pract. 2002;19(5):543–6.
13. WHO Collaborating Centre for Drug Statistics Methodology. 2015. Available
from: http://www.whocc.no/. Accessed 16 Jan 2017.
14. Luijks H, Schermer T, Bor H, van Weel C, Lagro-Janssen T, Biermans M, et al.
Prevalence and incidence density rates of chronic comorbidity in type 2
diabetes patients: an exploratory cohort study. BMC Med. 2012;10:128.
15. Snoeck-Stroband JB, Schermer TRJ, Van Schayck CP, Muris JW, Van der
Molen T, In ’t Veen JCCM, Chavannes NH, Broekhuizen BDL, Barnhoorn MJM,
Smeele I, Geijer RMM, Tuut MK. NHG guideline COPD (third revision).
Huisarts Wet. 2015;58(4):198–211.
16. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time
course and recovery of exacerbations in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–13.
17. Frei A, Muggensturm P, Putcha N, Siebeling L, Zoller M, Boyd CM, et al. Five
comorbidities reflected the health status in patients with chronic
obstructive pulmonary disease: the newly developed COMCOLD index. J
Clin Epidemiol. 2014;67(8):904–11.
18. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al.
Unrecognized heart failure in elderly patients with stable chronic
obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887–94.
19. Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso Ortiz MB, Murio C, et al.
Comorbidities and short-term prognosis in patients hospitalized for acute
exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI)
study. Chest. 2012;142(5):1126–33.
20. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, et al. Independent effect
of depression and anxiety on chronic obstructive pulmonary disease
exacerbations and hospitalizations. Am J Respir Crit Care Med. 2008;178(9):
913–20.
21. Kruis AL, Stallberg B, Jones RC, Tsiligianni IG, Lisspers K, van der Molen T, et
al. Primary care COPD patients compared with large pharmaceutically-
sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9(3):
e90145.
22. Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J.
Statin use and exacerbations in individuals with chronic obstructive
pulmonary disease. Thorax. 2015;70(1):33–40.
23. Chan MC, Lin CH, Kou YR. Hyperlipidemia in COPD is associated with
decreased incidence of pneumonia and mortality a nationwide health
insurance data based retrospective cohort study. Int J Chron Obstruct
Pulmon Dis. 2016;11:1053–9.
24. de Vries M, Berendsen AJ, Bosveld HE, Kerstjens HA, van der Molen T. COPD
exacerbations in general practice: variability in oral prednisolone courses.
BMC Fam Pract. 2012;13:3.
25. Lee AL, Goldstein RS. Gastroesophageal reflux disease in COPD: links and
risks. Int J Chron Obstruct Pulmon Dis. 2015;10:1935–49.
26. Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, et
al. Management of COPD in the UK primary-care setting: an analysis of
real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis.
2014;9:889–904.
27 James GD, Donaldson GC, Wedzicha JA, Nazareth I. Trends in management
and outcomes of COPD patients in primary care, 2000–2009: a retrospective
cohort study. NPJ Prim Care Respir Med. 2014;24:14015.
28. Jones PW, Nadeau G, Small M, Adamek L. Characteristics of a COPD
population categorised using the GOLD framework by health status and
exacerbations. Respir Med. 2014;108(1):129–35.
29. Lange P, Tottenborg SS, Sorknaes AD, Andersen JS, Sogaard M, Nielsen H, et
al. Danish Register of chronic obstructive pulmonary disease. Clin Epidemiol.
2016;8:673–8.
30. Triest FJ, Franssen FM, Spruit MA, Groenen MT, Wouters EF, Vanfleteren LE.
Poor agreement between chart-based and objectively identified
comorbidities of COPD. Eur Respir J. 2015;46(5):1492–5.
31. Vanfleteren LE, Franssen FM, Uszko-Lencer NH, Spruit MA, Celis M, Gorgels
AP, et al. Frequency and relevance of ischemic electrocardiographic findings
in patients with chronic obstructive pulmonary disease. Am J Cardiol.
2011;108(11):1669–74.
32. Dijk WD, Bemt L, Haak-Rongen S, Bischoff E, Weel C, Veen JC, et al.
Multidimensional prognostic indices for use in COPD patient care. A
systematic review. Respir Res. 2011;12:151.
33. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M,
Harding S, et al. Derivation and validation of a composite index of severity
in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit
Care Med. 2009;180(12):1189–95.
34. Rolink M, van Dijk W, van den Haak-Rongen S, Pieters W, Schermer T, van
den Bemt L. Using the DOSE index to predict changes in health status of
patients with COPD: a prospective cohort study. Prim Care Respir J.
2013;22(2):169–74.
35. Numans ME, De Wit NJ, Dirven JAM, Heemstra-Borst CG, Hurenkamp GJB,
Scheele ME, Burgers JS, Geijer RMM, De Jongh E. NHG guideline Stomach
complaints (third revision). Huisarts Wet. 2013;56:26–3.
36. Smeele I, Barnhoorn MJM, Broekhuizen BDL, Chavannes NH, In ’t Veen
JCCM, Van der Molen T, Muris JW, Van Schayck O, Schermer TRJ, Snoeck-
Stroband JB, Geijer RMM, Tuut MK. NHG-Werkgroep Astma bij volwassenen
en COPD. [NHG guideline Asthma in adults (third revision)]. Huisarts Wet.
2015;58(3):142–54.
37. Van Weel-Baumgarten EM, Van Gelderen MG, Grundmeijer HGLM, Licht-
Strunk E, Van Marwijk HWJ, Van Rijswijk HCAM, Tjaden BR, Verduijn M,
Wiersma T, Burgers JS, Van Avendonk MJP, Van der Weele GM. [NHG
guideline Depression (second revision). Huisarts Wet. 2012;55(6):252–9.
38. Spijker J, Bockting CLH, Meeuwissen JAC, Vliet IM V, Emmelkamp PMG,
Hermens MLM, Balkom ALJM V, namens de Werkgroep Multidisciplinaire
richtlijnontwikkeling Angststoornissen/Depressie. Multidisciplinaire richtlijn
Depressie (Derde revisie). Richtlijn voor de diagnostiek, behandeling en
begeleiding van volwassen patiënten met een depressieve stoornis. Utrecht:
Trimbos-instituut; 2013.
39. Hassink-Franke LJA, Terluin B, Van Heest FB, Hekman J, Van Marwijk HWJ,
Van Avendonk MJP. [NHG guideline Anxiety (second revision)]. Huisarts Wet.
2012;55(2):68-77.
40. Van Hof N, Balak FSR, Apeldoorn L, De Nooijer HJ, Vleesch Dubois V. Van
Rijn-van Kortenhof. [NHG guideline Ulcus cruris venosum (second revision)].
Huisarts Wet. 2010;53(6):321–33.
41. Van Pinxteren B, Knottnerus BJ, Geerlings SE, Visser HS, Klinkhamer S, Van
der Weele GM, Verduijn MM, Opstelten W, Burgers JS, Van Asselt KM. [NHG-
guideline Urinary tract infections (third revision)]. Huisarts Wet. 2013;56(6):
270–80.
42. Janssens HJEM, Lagro HAHM, Van Peet PG, Gorter KJ, Van der Pas P, Van der
Paardt M, Woutersen-Koch H. [NHG guideline osteoarthritis (first version)].
Huisarts Wet. 2009;52(9):439–53.
Westerik et al. Respiratory Research  (2017) 18:31 Page 16 of 17
43. Bouma M, Burgers J, Drost B, Den Elzen WPJ, Luchtman T, OosterhuisWP,
Woutersen-Koch H, Van Wijk M; NHG-werkgroep Anemie. [NHG
guideline anemia (first revision)]. Huisarts Wet. 2014;57(10):528–36.
44. Dekker F, Van Duijn NP, Ongering JEP, Bartelink MEL, Boelman L, Burgers JS,
Bouma M, Kurver MJ. [NHG guideline Headache (third revision)]. Huisarts
Wet. 2014;57(1):20–31.
45. Venekamp RP, De Sutter A, Sachs A, Bons SCS, Wiersma TJ, De Jongh E.
[NHG guideline Acute rhinosinusitis (third revision)]. Huisarts Wet. 2014;
57(10):537.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Westerik et al. Respiratory Research  (2017) 18:31 Page 17 of 17
